Optibrium

Optibrium Previews Derek Nexus for StarDrop in Hands-On Workshop at ACS Spring National Meeting

OptibriumToxicity of drug candidates is a major cause of expensive, late-stage failure in pre-clinical and clinical development.  At the ACS Spring 2013 National Meeting, Optibrium™ is previewing the Derek Nexus™ module for their StarDrop™ software platform discovery. This new module provides Lhasa Limited’s world-leading technology for knowledge-based prediction of key toxicities, integrated within StarDrop to help guide the design and selection of high quality compounds in drug discovery.

Optibrium will introduce the new Derek Nexus module at a free lunchtime workshop “Addressing toxicity in drug discovery.” This workshop will include a presentation by David Watson, CEO of Lhasa Limited, introducing their Derek Nexus platform, and a hands-on opportunity to try StarDrop. The workshop will be held on Tuesday, April 9th from 12:00 – 2:30 pm in Halls B2-C, Exhibitor Workshop Room 1 and lunch will be provided. Places are limited, so please register at www.optibrium.com or with the Optibrium team at booth #708 in the Exposition.

Using data from published and donated sources, Lhasa Limited’s Derek Nexus technology identifies structure-toxicity relationships that alert users to potential causes of compound toxicity in over 40 endpoints, including mutagenicity, hepatotoxicity and cardiotoxicity.

Optibrium’s StarDrop software platform guides decisions in drug discovery to quickly identify chemistries with a high chance of success against a drug discovery project’s objectives. StarDrop’s unique probabilistic scoring approach to multi-parameter optimisation allows predicted and experimental data to be given appropriate weights when balancing the many requirements for a high quality lead or candidate compound.

The combination of these technologies will enable chemists to intuitively balance the reduction of toxicity risk with the other requirements for a successful, safe and efficacious drug in hit-to-lead and lead optimisation. Furthermore, the region of a compound triggering a toxicity alert will be highlighted using StarDrop’s Glowing Molecule™ visualisation, helping to guide the interactive redesign of compounds to reduce liabilities.

If you aren’t attending the ACS Spring meeting you can find out more about StarDrop and Optibrium’s collaboration with Lhasa Limited at www.optibrium.com. Alternatively, call +44 1223 815 900 or email info@optibrium.com for more information.